Podcast: Novartis, ML&P and ex-GSK counsel on COVID pools

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Podcast: Novartis, ML&P and ex-GSK counsel on COVID pools

re-podcast-logo.png

Guests debate how patent pools could be used to ensure global access to COVID treatments and vaccines, as well as how the pandemic has changed the IP system


To listen to the podcast, which is nearly 50 minutes, click the link below.

For the first Managing IP podcast, Charlotte Kilpatrick and IP experts discussed the ramifications of the COVID-19 crisis on the patent system and how the virus could change how pharma innovators conduct research and collaborate.

A highlight was a debate on the role patent pools could play to accelerate research for COVID treatments and vaccines. Ellen 't Hoen, director of the Medicines Law and Policy research institute in the Netherlands, stressed the importance for pharma innovators to use patent pools as a way to ensure global access to the vaccines once they become available. She pointed to the example of the Medicines Patent Pool, which negotiates licences for HIV and tuberculosis medications with generics companies, which can produce treatments at an affordable cost for developing countries.

David Rosenberg, former vice president of IP policy at GSK, agreed that a patent pool could be one solution among many to ensure access, but added he doesn’t believe a pool will be the ideal way for companies to conduct business and that innovators are more confident to negotiate with generics companies they already know. 

Corey Salsberg, vice president and global head of IP affairs at Novartis in Washington DC, noted that because tackling COVID-19 could involve multiple vaccines as well as treatments for those with advanced symptoms, a single patent pool might not be the best solution to ensure access.

Enjoy the podcast. 








more from across site and SHARED ros bottom lb

More from across our site

A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points this fortnight
Managing IP considers some of the key themes from the 2025 Annual Meeting and offers some tips for London 2026
A comparison of the 2024 and 2025 editions of the Managing IP EMEA Awards reveals the firms and companies that have been dominating Europe’s IP market year after year
Tuesday's coverage includes BD tips for aspiring partners, and a foray into the world of SEPs
Exclusive data reveals law firms are failing to go above and beyond for their corporate clients, with in-house counsel saying advisers should consider more transparent billing processes
Arty Rajendra and Gary Moss discuss why ‘thorough and intense’ preparation, plus the odd glass of wine, led to a record FRAND victory for their client
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Managing IP gives a taster of the numbers behind this year’s IP STARS trademark rankings, and looks back at our 2025 award winners
Updates from IP offices, the shifting requirements of in-house counsel, and news of London 2026 were among major talking points on Sunday
Etienne Sanz de Acedo discusses the association’s three-year plan, what he is looking forward to in San Diego, and why London came calling for 2026
Gift this article